Wedbush upgrades STAAR Surgical stock rating on China rebound By Investing.com

Wedbush upgraded STAAR Surgical to Outperform from Neutral and raised its price target to $40 from $26, citing an inflection point in the China recovery and potential multiple expansion. The company also reported Q1 2026 EPS of $0.10 versus $0.05 expected and revenue of $93.5 million versus $78.74 million expected, helped by strong EVO+ lens demand in China and a record U.S. quarter. Management expects to generate cash this year as STAAR returns to profitability.

Analysis

The market is beginning to treat STAA less like a “China optionality” story and more like a re-rating candidate on operating leverage. That matters because once the China recovery starts to show up in sustained unit growth, incremental revenue should disproportionately drop to EBITDA and free cash flow; in a still-recovering profitability base, even modest volume upside can create outsized estimate revisions over the next 2-3 quarters. The second-order effect is that suppliers and adjacent med-tech names with China exposure may see sympathy bids, but STAA is the cleaner expression because the catalyst is product-specific rather than broad discretionary demand.

The key risk is that the stock can outrun the actual pace of China normalization. If the rebound is choppy rather than linear, multiple expansion can stall even while the business keeps improving, because the market is already pricing an inflection and will demand sequential proof. Another hidden vulnerability is channel inventory and procedure timing: a strong quarter can be followed by a softer one if clinics pull forward purchases or patient backlogs normalize faster than expected. That makes the next 1-2 earnings prints more important than the annual story.

From a positioning standpoint, this is a good name for a staged long rather than an outright chase. The consensus is probably underestimating how much of the upside can come from valuation compression reversing toward prior growth-era levels, but it may be overestimating the speed at which that happens. The asymmetry is best expressed through defined-risk upside exposure, because a clean China beat can re-rate the multiple quickly, while disappointment likely leads to a sharp de-rating given how much optimism is now embedded.

Key Decisions for Investors

• Initiate a starter long in STAA on any post-upgrade consolidation over the next 1-2 sessions; use a 3-6 month horizon and size for a 2-3x upside vs. ~15-20% downside if China momentum decelerates.
• Prefer STAA calls over common for the next earnings cycle: buy 3-6 month out-of-the-money calls to express upside from further China recovery with limited capital at risk; ideal if implied vol remains below historical post-earnings levels.
• Pair trade: long STAA / short a lower-quality med-tech peer with weaker growth visibility over the next quarter to isolate the China rebound and product-mix upside; target relative outperformance if estimates continue to move higher.
• If already long, trim only on a failed follow-through quarter, not on headline multiple expansion alone; the thesis breaks on sequential slowdown, not on rich valuation.
• Watch for evidence of channel normalization and cash flow inflection over the next 1-2 earnings releases; if both confirm, add on strength rather than waiting for a pullback.